Lilly’s phase III retatrutide wins in A1C dips and weight loss for T2D patients

AI Briefing

• – Retruttide shows promise in phase III trials for T2D patients
• – Study results indicate statistically significant reductions in A1C levels and weight loss
• – Pharma companies await FDA approval for potential new treatment for type 2 diabetes